ImmuCell Corp Files Q3 2024 10-Q

TL;DR

ImmuCell Corp filed its Q3 10-Q, check Nasdaq:ICCC for updates.

AI Summary

ImmuCell Corporation filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Delaware, reported its financial status and business operations. ImmuCell Corporation's common stock is traded on The Nasdaq Capital Market under the symbol ICCC.

Why It Matters

This filing provides investors with an update on ImmuCell Corporation's financial performance and operational status for the third quarter of 2024.

Risk Assessment

Risk Level: medium — As a publicly traded company filing quarterly reports, ImmuCell Corporation is subject to market and regulatory risks inherent in the life sciences sector.

Key Numbers

• 001-12934 — SEC File Number (Identifies the company's filings with the SEC.)
• 01-0382980 — IRS Number (Company's Employer Identification Number.)

Key Players & Entities

• ImmuCell Corporation (company) — Registrant
• September 30, 2024 (date) — Quarterly period end date
• Delaware (location) — State of Incorporation
• ICCC (ticker) — Trading symbol on Nasdaq Capital Market
• The Nasdaq Capital Market (company) — Exchange where common stock is registered

FAQ

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 par value per share ICCC The Nasdaq Cap

Filing Documents

• ea0220527-10q_immucell.htm (10-Q) — 1299KB
• ea022052701ex31_immucell.htm (EX-31) — 14KB
• ea022052701ex32_immucell.htm (EX-32) — 5KB
• image_001.jpg (GRAPHIC) — 123KB
• image_002.jpg (GRAPHIC) — 108KB
• 0001213900-24-097450.txt ( ) — 8083KB
• iccc-20240930.xsd (EX-101.SCH) — 58KB
• iccc-20240930_cal.xml (EX-101.CAL) — 41KB
• iccc-20240930_def.xml (EX-101.DEF) — 308KB
• iccc-20240930_lab.xml (EX-101.LAB) — 550KB
• iccc-20240930_pre.xml (EX-101.PRE) — 323KB
• ea0220527-10q_immucell_htm.xml (XML) — 1127KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION ITEM 1. Unaudited Financial Statements Balance Sheets as of September 30, 2024 and December 31, 2023 1 2 3 4-5 Notes to Unaudited Financial Statements 6-26 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27-47 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 47 ITEM 4.

Controls and Procedures

Controls and Procedures 47

: OTHER INFORMATION

PART II: OTHER INFORMATION

THROUGH 6

ITEM 1 THROUGH 6. 48-58 Signature 59 i ImmuCell Corporation Part 1. FINANCIAL INFORMATION

UNAUDITED FINANCIAL STATEMENTS

ITEM 1. UNAUDITED FINANCIAL STATEMENTS BALANCE SHEETS (Unaudited) As of September 30, 2024 As of December 31, 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 3,808,633 $ 978,741 Trade accounts receivable 2,307,913 2,185,383 Inventory 7,460,452 7,811,841 Prepaid expenses and other current assets 310,488 493,885 Total current assets 13,887,486 11,469,850 Property, plant and equipment, net 25,820,333 27,575,683 Operating lease right-of-use asset 4,592,718 4,571,149 Goodwill 95,557 95,557 Intangible assets, net 23,880 38,208 Other assets 28,899 57,655 TOTAL ASSETS $ 44,448,873 $ 43,808,102 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current portion of debt obligations $ 1,479,058 $ 1,428,807 Current portion of operating lease liability 482,244 644,276 Accounts payable and accrued expenses 2,504,535 2,124,337 Total current liabilities 4,465,837 4,197,420 LONG-TERM LIABILITIES: Debt obligations, net of current portion 9,422,961 10,540,496 Operating lease liability, net of current portion 4,148,404 4,077,109 Total long-term liabilities 13,571,365 14,617,605 TOTAL LIABILITIES 18,037,202 18,815,025 CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11) STOCKHOLDER' EQUITY: Common stock, $ 0.10 par value per share, 15,000,000 and 15,000,000 shares authorized, 8,896,398 and 7,814,165 shares issued and 8,833,097 and 7,750,864 shares outstanding, as of September 30, 2024 and December 31, 2023, respectively. 889,641 781,417 Additional paid-in capital 40,338,793 36,357,239 Accumulated deficit ( 14,678,281 ) ( 12,007,097 ) Treasury stock, at cost, 63,301 shares as of both September 30, 2024 and December 31, 2023 ( 138,482 ) ( 138,482 ) TOTAL STOCKHOLDERS' EQUITY 26,411,671 24,993,077 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 44,448,873 $ 43,808,102 The accompanying notes are an integral part of these unaudited financial statements.

View Full Filing

View this 10-Q filing on SEC EDGAR